Neurometrix Inc  

(Public, NASDAQ:NURO)   Watch this stock  
Find more results for nuro
1.73
+0.05 (2.98%)
Jun 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.63 - 1.75
52 week 1.35 - 4.96
Open 1.63
Vol / Avg. 110,055.00/82,241.00
Mkt cap 8.01M
P/E     -
Div/yield     -
EPS -7.31
Shares 4.39M
Beta 0.74
Inst. own 7%
Jul 20, 2016
Q2 2016 NeuroMetrix Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Apr 26, 2016
NeuroMetrix Inc at First Look Equities Summit
Apr 21, 2016
Q1 2016 NeuroMetrix Inc Earnings Release
Apr 21, 2016
Q1 2016 NeuroMetrix Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -179.99% -125.86%
Operating margin -184.43% -181.87%
EBITD margin - -178.82%
Return on average assets -115.91% -66.97%
Return on average equity -153.41% -264.21%
Employees 48 -
CDP Score - -

Address

1000 Winter St
WALTHAM, MA 02451-1436
United States - Map
+1-781-8909989 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NeuroMetrix, Inc. (NeuroMetrix) is a health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain, nerve diseases and sleep disorders. The Company operates through the sale of medical equipment and consumables segment. Its products are sold in the United States and selected overseas markets. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The Company's products consist of a medical device used in conjunction with a consumable electrode or biosensor. Its products include Quell, which is a wearable device for relief of chronic intractable pain; SENSUS, which is a prescription neuro-stimulation device; DPNCheck, which is a nerve conduction test that is used to evaluate systemic neuropathies, and ADVANCE System, which is a platform for the performance of nerve conduction studies.

Officers and directors

Shai N. Gozani M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer, Secretary
Age: 50
Bio & Compensation  - Reuters
Thomas T. Higgins Chief Financial Officer, Senior Vice President, Treasurer
Age: 63
Bio & Compensation  - Reuters
Francis X. McGillin Senior Vice President, General Manager - Consumer Wearables
Age: 54
Bio & Compensation  - Reuters
David E. Goodman M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Allen J. Hinkle M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Nancy E. Katz Independent Director
Age: 55
Bio & Compensation  - Reuters
Timothy R. Surgenor Independent Director
Age: 55
Bio & Compensation  - Reuters
David Van Avermaete Independent Director
Age: 63
Bio & Compensation  - Reuters